MDxHealth SA (NASDAQ:MDXH) Stock Has Average Target Price of $2.17

MDxHealth SA (NASDAQ:MDXH) has received an average recommendation of “Hold” from the five ratings firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $2.17.

Several research firms have recently weighed in on MDXH. Lake Street Capital set a $3.00 price objective on shares of MDxHealth and gave the stock a “buy” rating in a report on Friday, August 14th. Wall Street Zen upgraded MDxHealth to a “sell” rating in a research report on Saturday, August 15th. Weiss Ratings lowered MDxHealth from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, September 8th. Finally, BTIG Research dropped their price target on MDxHealth from $4.00 to $2.00 and set a “buy” rating for the company in a report on Friday, August 21st.

Institutional Trading of MDxHealth

Several large investors have recently made changes to their positions in the business. Squarepoint Ops LLC acquired a new position in shares of MDxHealth during the second quarter worth approximately $82,000. Bank of America Corp DE increased its holdings in shares of MDxHealth by 213.9% in the first quarter. Bank of America Corp DE now owns 43,492 shares of the company’s stock valued at $100,000 after purchasing an additional 29,638 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of MDxHealth by 21.8% in the first quarter. Renaissance Technologies LLC now owns 304,700 shares of the company’s stock valued at $701,000 after purchasing an additional 54,600 shares in the last quarter. Finally, Perkins Capital Management Inc. raised its position in MDxHealth by 7.1% in the 1st quarter. Perkins Capital Management Inc. now owns 1,476,441 shares of the company’s stock worth $3,396,000 after purchasing an additional 97,500 shares during the last quarter.

MDxHealth Stock Performance

MDXH opened at $0.60 on Friday. The firm has a market cap of $29.69 million, a price-to-earnings ratio of -0.83 and a beta of 1.68. The firm’s 50-day simple moving average is $0.62 and its 200-day simple moving average is $1.04. MDxHealth has a twelve month low of $0.40 and a twelve month high of $5.33.

MDxHealth (NASDAQ:MDXH) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.01. The firm had revenue of $27.21 million for the quarter, compared to the consensus estimate of $26.14 million. As a group, sell-side analysts anticipate that MDxHealth will post -0.49 EPS for the current fiscal year.

MDxHealth Company Profile

MDxHealth is a precision diagnostics company focused on improving the detection, diagnosis and management of cancer. The company develops and commercializes molecular and genomic tests designed to help physicians assess cancer risk, guide treatment decisions and monitor patients, with a primary focus on urological cancers.

Its product portfolio includes ConfirmMDx, a tissue-based test intended to help identify men who may have clinically significant prostate cancer after a prior negative biopsy; SelectMDx, a urine-based test that helps assess the likelihood of clinically significant prostate cancer; and ResolveMDx, a molecular test designed to support prostate cancer risk assessment.